Sanofi Biotechnology
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
0
Ending by 2030
Jan 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 6 to 15, 2027 · next Feb 6
- 2 fees due Apr 1 to 3, 2027 · next Apr 1
- 1 fee due May 26, 2027The maintenance fee for Methods for Treating Severe Atopic Dermatitis by Administering an IL-4R Inhibitor (US 10,485,844) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Methods for Inhibiting Atherosclerosis by Administering an Inhibitor of PCSK9 (US 10,494,442) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Methods of Treating Cancer Pain by Administering a PD-1 Inhibitor (US 11,932,692) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
Recent changes
- 6 of the patents on this record were granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,083,176 | Human Antibodies to PCSK9 for Use in Methods of Treating Particular Groups of Subjects In force · Low confidence | In force | Low confidence | |
| US 11,246,925 | Human Antibodies to PCSK9 for Use in Methods of Treating Particular Groups of Subjects In force · Medium confidence | In force | Medium confidence | |
| US 9,561,155 | Method of Reducing Cholesterol Levels Using a Human ANTI-PCSK9 Antibody In force · High confidence | In force | High confidence | |
| US 9,682,013 | Pharmaceutical Compositions Comprising Human Antibodies to PCSK9 In force · High confidence | In force | High confidence | |
| US 10,927,435 | Compositions for the Treatment of Rheumatoid Arthritis and Methods of Using Same In force · Medium confidence | In force | Medium confidence | |
| US 9,574,004 | Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist In force · High confidence | In force | High confidence | |
| US 9,943,594 | Methods for the Treatment of Rheumatoid Arthritis In force · High confidence | In force | High confidence | |
| US 10,494,442 | Methods for Inhibiting Atherosclerosis by Administering an Inhibitor of PCSK9 In force · High confidence | In force | High confidence | |
| US 10,995,150 | Methods for Inhibiting Atherosclerosis by Administering an ANTI-PCSK9 Antibody In force · High confidence | In force | High confidence | |
| US 10,059,771 | Methods for Treating Nasal Polyposis by Administering an IL-4R Antagonist In force · High confidence | In force | High confidence |
Also on record, not counted in the 46: 6 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
26 pending · 23 abandoned